Top Stories
Latest Coverage
Why Does the Epstein-Barr Virus Cause Nasopharyngeal Carcinoma? Understanding High-Risk Factors and Early Warning Signs
Nasopharyngeal carcinoma (NPC) is a relatively common malignancy in southern China and Southeast Asia. Among its vari...
Nasopharyngeal carcinoma (NPC) is a relatively common malignancy in southern China and Southeast Asia. Among its vari...
Counterfeit PD-1 Drugs Are Increasing: How Can Patients Identify Legitimate Pharmaceutical Channels?
In recent years, PD-1/PD-L1 immunotherapy has rapidly transformed cancer treatment worldwide and become an important ...
In recent years, PD-1/PD-L1 immunotherapy has rapidly transformed cancer treatment worldwide and become an important ...
Why Are More Cancer Drugs Becoming Oral Therapies? The Current Landscape of Oral Targeted Therapy in China
Over the past two decades, the global oncology treatment landscape has undergone a major transformation. Traditional ...
Over the past two decades, the global oncology treatment landscape has undergone a major transformation. Traditional ...
Follicular Lymphoma Treatment Enters the Immunotherapy Era: Bispecific Antibodies Are Rising
Follicular lymphoma (FL) is one of the most common indolent B-cell non-Hodgkin lymphomas.
Follicular lymphoma (FL) is one of the most common indolent B-cell non-Hodgkin lymphomas.
Which GBM Patients May Benefit from Bevacizumab?
Glioblastoma (GBM) is one of the most aggressive primary brain tumors, characterized by rapid growth, extensive infil...
Glioblastoma (GBM) is one of the most aggressive primary brain tumors, characterized by rapid growth, extensive infil...
A Milestone for Targeted Protein Degradation: The World’s First PROTAC Drug Approved
On May 1, 2026, the U.S. Food and Drug Administration officially approved Vepdegestrant (trade name: Veppanu) for the...
On May 1, 2026, the U.S. Food and Drug Administration officially approved Vepdegestrant (trade name: Veppanu) for the...
